Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 8, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 370,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,490.5 pence per share; lowest price paid was 1,476 pence per share.
- Treasury Holdings (Settled): 494,951,327 shares, representing 9.16% of total issued share capital.
- Treasury Holdings (Including Unsettled): 495,691,327 shares, representing 10.10% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,907,504,633 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 370,000 shares. No other material changes to financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the 370,000 shares purchased based on the disclosed price range.
- Confirm the impact of the 10.10% treasury holding on the denominator for shareholder notification thresholds.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.